The association between diabetes medication and weight change in a non‐surgical weight management intervention: an intervention cohort study
Aim To compare weight change in a lifestyle‐based weight management programme between participants taking weight‐gaining, weight‐neutral/loss and mixed diabetes medications. Methods Electronic health records for individuals (≥ 18 years) with Type 2 diabetes who had been referred to a non‐surgical we...
Gespeichert in:
| Veröffentlicht in: | Diabetic medicine 2020-02, Vol.37 (2), p.248-255 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 255 |
|---|---|
| container_issue | 2 |
| container_start_page | 248 |
| container_title | Diabetic medicine |
| container_volume | 37 |
| creator | Aldekhail, N. M. Morrison, D. S. Khojah, H. Sloan, B. McLoone, P. MacNaughton, S. Shearer, R. Logue, J. |
| description | Aim
To compare weight change in a lifestyle‐based weight management programme between participants taking weight‐gaining, weight‐neutral/loss and mixed diabetes medications.
Methods
Electronic health records for individuals (≥ 18 years) with Type 2 diabetes who had been referred to a non‐surgical weight management programme between February 2008 and May 2014 were studied. Diabetes medications were classified into three categories based on their effect on body weight. In this intervention cohort study, weight change was calculated for participants attending two or more sessions.
Results
All 998 individuals who took oral diabetes medications and attended two or more sessions of weight management were included. Some 59.5% of participants were women, and participants had a mean BMI of 41.1 kg/m2 (women) and 40.2 kg/m2 (men). Of the diabetes medication combinations prescribed, 46.0% were weight‐neutral/loss, 41.3% mixed and 12.7% weight‐gaining. The mean weight change for participants on weight‐gaining and weight‐neutral/loss diabetes medications respectively was −2.5 kg [95% confidence interval (CI) −3.2 to −1.8) and −3.3 kg (95% CI −3.8 to −2.9) (P = 0.05) for those attending two or more sessions (n = 998). Compared with those prescribed weight‐neutral medications, participants prescribed weight‐gaining medication lost 0.86 kg less (95% CI 0.02 to 1.7; P = 0.045) in a model adjusted for age, sex, BMI and socio‐economic status.
Conclusions
Participants on weight‐neutral/loss diabetes medications had a greater absolute weight loss within a weight management intervention compared with those on weight‐gaining medications. Diabetes medications should be reviewed ahead of planned weight‐loss interventions to help ensure maximal effectiveness of the intervention.
What's new?
Many oral diabetes medications are associated with weight gain, which makes the management of Type 2 diabetes in individuals with overweight and obesity more challenging.
There was a clinically significant larger weight loss in individuals on weight‐neutral/loss diabetes medication compared with those on weight‐gaining medication.
There is a gradated relationship between greater use of weight‐gaining diabetes medication and lower success of a weight‐loss programme.
Diabetes medication regimens should be reviewed prior to referral to a weight management programme to ensure that, when possible, weight neutral/loss medications are used preferentially over weight‐gaining medications. |
| doi_str_mv | 10.1111/dme.14093 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2343382008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2343382008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-dbc6550b94ad48ed628614b9ceaa430c5f6c5bc563ef22276736d90a521f5ee43</originalsourceid><addsrcrecordid>eNp1kLtOwzAUQC0EoqUw8APIEhNDwO8mbKiUhwRigTly7Js2VeOAnVB14wsQ38iXYAggMeDFV9dHx9JBaJ-SYxrPia3hmAqS8Q00pEKJRIqMbqIhGQuWcDKmA7QTwoIQyjKebaMBp1xJKvgQvd7PAesQGlPptmocLqBdAThsKx1HCLgGW5n-TTuLV1DN5i02c-1mgKu4xK5x7y9vofOzCC5_iFo7PYMaXBupFvxznKLkNFr-LLBp5o1vcWg7u95FW6VeBtj7vkfo4WJ6P7lKbu4urydnN4nhacoTWxglJSkyoa1IwSqWKiqKzIDWghMjS2VkYaTiUDLGxmrMlc2IloyWEkDwETrsvY--eeogtPmi6byLX-aMC85TRkgaqaOeMr4JwUOZP_qq1n6dU5J_ls9j-fyrfGQPvo1dEZP9kj-pI3DSA6tqCev_Tfn57bRXfgCx8JDe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2343382008</pqid></control><display><type>article</type><title>The association between diabetes medication and weight change in a non‐surgical weight management intervention: an intervention cohort study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Aldekhail, N. M. ; Morrison, D. S. ; Khojah, H. ; Sloan, B. ; McLoone, P. ; MacNaughton, S. ; Shearer, R. ; Logue, J.</creator><creatorcontrib>Aldekhail, N. M. ; Morrison, D. S. ; Khojah, H. ; Sloan, B. ; McLoone, P. ; MacNaughton, S. ; Shearer, R. ; Logue, J.</creatorcontrib><description>Aim
To compare weight change in a lifestyle‐based weight management programme between participants taking weight‐gaining, weight‐neutral/loss and mixed diabetes medications.
Methods
Electronic health records for individuals (≥ 18 years) with Type 2 diabetes who had been referred to a non‐surgical weight management programme between February 2008 and May 2014 were studied. Diabetes medications were classified into three categories based on their effect on body weight. In this intervention cohort study, weight change was calculated for participants attending two or more sessions.
Results
All 998 individuals who took oral diabetes medications and attended two or more sessions of weight management were included. Some 59.5% of participants were women, and participants had a mean BMI of 41.1 kg/m2 (women) and 40.2 kg/m2 (men). Of the diabetes medication combinations prescribed, 46.0% were weight‐neutral/loss, 41.3% mixed and 12.7% weight‐gaining. The mean weight change for participants on weight‐gaining and weight‐neutral/loss diabetes medications respectively was −2.5 kg [95% confidence interval (CI) −3.2 to −1.8) and −3.3 kg (95% CI −3.8 to −2.9) (P = 0.05) for those attending two or more sessions (n = 998). Compared with those prescribed weight‐neutral medications, participants prescribed weight‐gaining medication lost 0.86 kg less (95% CI 0.02 to 1.7; P = 0.045) in a model adjusted for age, sex, BMI and socio‐economic status.
Conclusions
Participants on weight‐neutral/loss diabetes medications had a greater absolute weight loss within a weight management intervention compared with those on weight‐gaining medications. Diabetes medications should be reviewed ahead of planned weight‐loss interventions to help ensure maximal effectiveness of the intervention.
What's new?
Many oral diabetes medications are associated with weight gain, which makes the management of Type 2 diabetes in individuals with overweight and obesity more challenging.
There was a clinically significant larger weight loss in individuals on weight‐neutral/loss diabetes medication compared with those on weight‐gaining medication.
There is a gradated relationship between greater use of weight‐gaining diabetes medication and lower success of a weight‐loss programme.
Diabetes medication regimens should be reviewed prior to referral to a weight management programme to ensure that, when possible, weight neutral/loss medications are used preferentially over weight‐gaining medications.</description><identifier>ISSN: 0742-3071</identifier><identifier>EISSN: 1464-5491</identifier><identifier>DOI: 10.1111/dme.14093</identifier><identifier>PMID: 31365143</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Body Mass Index ; Body weight ; Body weight gain ; Body weight loss ; Cohort analysis ; Cohort Studies ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Electronic medical records ; Female ; Humans ; Hypoglycemic Agents - classification ; Hypoglycemic Agents - therapeutic use ; Incretins - therapeutic use ; Intervention ; Male ; Metformin - therapeutic use ; Middle Aged ; Obesity - complications ; Obesity - therapy ; Obesity Management ; Retrospective Studies ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use ; Sulfonylurea Compounds - adverse effects ; Sulfonylurea Compounds - therapeutic use ; Thiazolidinediones - adverse effects ; Thiazolidinediones - therapeutic use ; Weight control ; Weight Gain ; Weight Loss ; Weight Reduction Programs ; Young Adult</subject><ispartof>Diabetic medicine, 2020-02, Vol.37 (2), p.248-255</ispartof><rights>2019 Diabetes UK</rights><rights>2019 Diabetes UK.</rights><rights>Diabetic Medicine © 2020 Diabetes UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-dbc6550b94ad48ed628614b9ceaa430c5f6c5bc563ef22276736d90a521f5ee43</citedby><cites>FETCH-LOGICAL-c3883-dbc6550b94ad48ed628614b9ceaa430c5f6c5bc563ef22276736d90a521f5ee43</cites><orcidid>0000-0003-4856-1969 ; 0000-0001-9549-2738</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdme.14093$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdme.14093$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31365143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aldekhail, N. M.</creatorcontrib><creatorcontrib>Morrison, D. S.</creatorcontrib><creatorcontrib>Khojah, H.</creatorcontrib><creatorcontrib>Sloan, B.</creatorcontrib><creatorcontrib>McLoone, P.</creatorcontrib><creatorcontrib>MacNaughton, S.</creatorcontrib><creatorcontrib>Shearer, R.</creatorcontrib><creatorcontrib>Logue, J.</creatorcontrib><title>The association between diabetes medication and weight change in a non‐surgical weight management intervention: an intervention cohort study</title><title>Diabetic medicine</title><addtitle>Diabet Med</addtitle><description>Aim
To compare weight change in a lifestyle‐based weight management programme between participants taking weight‐gaining, weight‐neutral/loss and mixed diabetes medications.
Methods
Electronic health records for individuals (≥ 18 years) with Type 2 diabetes who had been referred to a non‐surgical weight management programme between February 2008 and May 2014 were studied. Diabetes medications were classified into three categories based on their effect on body weight. In this intervention cohort study, weight change was calculated for participants attending two or more sessions.
Results
All 998 individuals who took oral diabetes medications and attended two or more sessions of weight management were included. Some 59.5% of participants were women, and participants had a mean BMI of 41.1 kg/m2 (women) and 40.2 kg/m2 (men). Of the diabetes medication combinations prescribed, 46.0% were weight‐neutral/loss, 41.3% mixed and 12.7% weight‐gaining. The mean weight change for participants on weight‐gaining and weight‐neutral/loss diabetes medications respectively was −2.5 kg [95% confidence interval (CI) −3.2 to −1.8) and −3.3 kg (95% CI −3.8 to −2.9) (P = 0.05) for those attending two or more sessions (n = 998). Compared with those prescribed weight‐neutral medications, participants prescribed weight‐gaining medication lost 0.86 kg less (95% CI 0.02 to 1.7; P = 0.045) in a model adjusted for age, sex, BMI and socio‐economic status.
Conclusions
Participants on weight‐neutral/loss diabetes medications had a greater absolute weight loss within a weight management intervention compared with those on weight‐gaining medications. Diabetes medications should be reviewed ahead of planned weight‐loss interventions to help ensure maximal effectiveness of the intervention.
What's new?
Many oral diabetes medications are associated with weight gain, which makes the management of Type 2 diabetes in individuals with overweight and obesity more challenging.
There was a clinically significant larger weight loss in individuals on weight‐neutral/loss diabetes medication compared with those on weight‐gaining medication.
There is a gradated relationship between greater use of weight‐gaining diabetes medication and lower success of a weight‐loss programme.
Diabetes medication regimens should be reviewed prior to referral to a weight management programme to ensure that, when possible, weight neutral/loss medications are used preferentially over weight‐gaining medications.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Body Mass Index</subject><subject>Body weight</subject><subject>Body weight gain</subject><subject>Body weight loss</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Electronic medical records</subject><subject>Female</subject><subject>Humans</subject><subject>Hypoglycemic Agents - classification</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Incretins - therapeutic use</subject><subject>Intervention</subject><subject>Male</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Obesity - complications</subject><subject>Obesity - therapy</subject><subject>Obesity Management</subject><subject>Retrospective Studies</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</subject><subject>Sulfonylurea Compounds - adverse effects</subject><subject>Sulfonylurea Compounds - therapeutic use</subject><subject>Thiazolidinediones - adverse effects</subject><subject>Thiazolidinediones - therapeutic use</subject><subject>Weight control</subject><subject>Weight Gain</subject><subject>Weight Loss</subject><subject>Weight Reduction Programs</subject><subject>Young Adult</subject><issn>0742-3071</issn><issn>1464-5491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLtOwzAUQC0EoqUw8APIEhNDwO8mbKiUhwRigTly7Js2VeOAnVB14wsQ38iXYAggMeDFV9dHx9JBaJ-SYxrPia3hmAqS8Q00pEKJRIqMbqIhGQuWcDKmA7QTwoIQyjKebaMBp1xJKvgQvd7PAesQGlPptmocLqBdAThsKx1HCLgGW5n-TTuLV1DN5i02c-1mgKu4xK5x7y9vofOzCC5_iFo7PYMaXBupFvxznKLkNFr-LLBp5o1vcWg7u95FW6VeBtj7vkfo4WJ6P7lKbu4urydnN4nhacoTWxglJSkyoa1IwSqWKiqKzIDWghMjS2VkYaTiUDLGxmrMlc2IloyWEkDwETrsvY--eeogtPmi6byLX-aMC85TRkgaqaOeMr4JwUOZP_qq1n6dU5J_ls9j-fyrfGQPvo1dEZP9kj-pI3DSA6tqCev_Tfn57bRXfgCx8JDe</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Aldekhail, N. M.</creator><creator>Morrison, D. S.</creator><creator>Khojah, H.</creator><creator>Sloan, B.</creator><creator>McLoone, P.</creator><creator>MacNaughton, S.</creator><creator>Shearer, R.</creator><creator>Logue, J.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0003-4856-1969</orcidid><orcidid>https://orcid.org/0000-0001-9549-2738</orcidid></search><sort><creationdate>202002</creationdate><title>The association between diabetes medication and weight change in a non‐surgical weight management intervention: an intervention cohort study</title><author>Aldekhail, N. M. ; Morrison, D. S. ; Khojah, H. ; Sloan, B. ; McLoone, P. ; MacNaughton, S. ; Shearer, R. ; Logue, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-dbc6550b94ad48ed628614b9ceaa430c5f6c5bc563ef22276736d90a521f5ee43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Body Mass Index</topic><topic>Body weight</topic><topic>Body weight gain</topic><topic>Body weight loss</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Electronic medical records</topic><topic>Female</topic><topic>Humans</topic><topic>Hypoglycemic Agents - classification</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Incretins - therapeutic use</topic><topic>Intervention</topic><topic>Male</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Obesity - complications</topic><topic>Obesity - therapy</topic><topic>Obesity Management</topic><topic>Retrospective Studies</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</topic><topic>Sulfonylurea Compounds - adverse effects</topic><topic>Sulfonylurea Compounds - therapeutic use</topic><topic>Thiazolidinediones - adverse effects</topic><topic>Thiazolidinediones - therapeutic use</topic><topic>Weight control</topic><topic>Weight Gain</topic><topic>Weight Loss</topic><topic>Weight Reduction Programs</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aldekhail, N. M.</creatorcontrib><creatorcontrib>Morrison, D. S.</creatorcontrib><creatorcontrib>Khojah, H.</creatorcontrib><creatorcontrib>Sloan, B.</creatorcontrib><creatorcontrib>McLoone, P.</creatorcontrib><creatorcontrib>MacNaughton, S.</creatorcontrib><creatorcontrib>Shearer, R.</creatorcontrib><creatorcontrib>Logue, J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Diabetic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aldekhail, N. M.</au><au>Morrison, D. S.</au><au>Khojah, H.</au><au>Sloan, B.</au><au>McLoone, P.</au><au>MacNaughton, S.</au><au>Shearer, R.</au><au>Logue, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The association between diabetes medication and weight change in a non‐surgical weight management intervention: an intervention cohort study</atitle><jtitle>Diabetic medicine</jtitle><addtitle>Diabet Med</addtitle><date>2020-02</date><risdate>2020</risdate><volume>37</volume><issue>2</issue><spage>248</spage><epage>255</epage><pages>248-255</pages><issn>0742-3071</issn><eissn>1464-5491</eissn><abstract>Aim
To compare weight change in a lifestyle‐based weight management programme between participants taking weight‐gaining, weight‐neutral/loss and mixed diabetes medications.
Methods
Electronic health records for individuals (≥ 18 years) with Type 2 diabetes who had been referred to a non‐surgical weight management programme between February 2008 and May 2014 were studied. Diabetes medications were classified into three categories based on their effect on body weight. In this intervention cohort study, weight change was calculated for participants attending two or more sessions.
Results
All 998 individuals who took oral diabetes medications and attended two or more sessions of weight management were included. Some 59.5% of participants were women, and participants had a mean BMI of 41.1 kg/m2 (women) and 40.2 kg/m2 (men). Of the diabetes medication combinations prescribed, 46.0% were weight‐neutral/loss, 41.3% mixed and 12.7% weight‐gaining. The mean weight change for participants on weight‐gaining and weight‐neutral/loss diabetes medications respectively was −2.5 kg [95% confidence interval (CI) −3.2 to −1.8) and −3.3 kg (95% CI −3.8 to −2.9) (P = 0.05) for those attending two or more sessions (n = 998). Compared with those prescribed weight‐neutral medications, participants prescribed weight‐gaining medication lost 0.86 kg less (95% CI 0.02 to 1.7; P = 0.045) in a model adjusted for age, sex, BMI and socio‐economic status.
Conclusions
Participants on weight‐neutral/loss diabetes medications had a greater absolute weight loss within a weight management intervention compared with those on weight‐gaining medications. Diabetes medications should be reviewed ahead of planned weight‐loss interventions to help ensure maximal effectiveness of the intervention.
What's new?
Many oral diabetes medications are associated with weight gain, which makes the management of Type 2 diabetes in individuals with overweight and obesity more challenging.
There was a clinically significant larger weight loss in individuals on weight‐neutral/loss diabetes medication compared with those on weight‐gaining medication.
There is a gradated relationship between greater use of weight‐gaining diabetes medication and lower success of a weight‐loss programme.
Diabetes medication regimens should be reviewed prior to referral to a weight management programme to ensure that, when possible, weight neutral/loss medications are used preferentially over weight‐gaining medications.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31365143</pmid><doi>10.1111/dme.14093</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4856-1969</orcidid><orcidid>https://orcid.org/0000-0001-9549-2738</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0742-3071 |
| ispartof | Diabetic medicine, 2020-02, Vol.37 (2), p.248-255 |
| issn | 0742-3071 1464-5491 |
| language | eng |
| recordid | cdi_proquest_journals_2343382008 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adolescent Adult Aged Body Mass Index Body weight Body weight gain Body weight loss Cohort analysis Cohort Studies Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Electronic medical records Female Humans Hypoglycemic Agents - classification Hypoglycemic Agents - therapeutic use Incretins - therapeutic use Intervention Male Metformin - therapeutic use Middle Aged Obesity - complications Obesity - therapy Obesity Management Retrospective Studies Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Sulfonylurea Compounds - adverse effects Sulfonylurea Compounds - therapeutic use Thiazolidinediones - adverse effects Thiazolidinediones - therapeutic use Weight control Weight Gain Weight Loss Weight Reduction Programs Young Adult |
| title | The association between diabetes medication and weight change in a non‐surgical weight management intervention: an intervention cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T18%3A44%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20association%20between%20diabetes%20medication%20and%20weight%20change%20in%20a%20non%E2%80%90surgical%20weight%20management%20intervention:%20an%20intervention%20cohort%20study&rft.jtitle=Diabetic%20medicine&rft.au=Aldekhail,%20N.%20M.&rft.date=2020-02&rft.volume=37&rft.issue=2&rft.spage=248&rft.epage=255&rft.pages=248-255&rft.issn=0742-3071&rft.eissn=1464-5491&rft_id=info:doi/10.1111/dme.14093&rft_dat=%3Cproquest_cross%3E2343382008%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2343382008&rft_id=info:pmid/31365143&rfr_iscdi=true |